Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
What Middle East Conflict Could Mean For The World’s Largest Whale Shark Gathering - 2German Easter peace marches draw tens of thousands
- 3Figure out How to Reveal Stowed away Open Record Rewards
- 4Displaced Palestinian families suffer as heavy rains flood Gaza tent camps
- 5Nearly 16,000 New York City nurses prepare to strike as contract talks stall
- Cyprus: War-related tourism concerns and climate change efforts
- Spain's Easter processions draw more tourists amid Iran war
- Barry Manilow to have surgery for early-stage lung cancer and postpones January concerts
- Washington state experiences historic flooding as Skagit River hits record high level. See flooding maps, highway closures and forecasts.
- Tatiana Schlossberg, a granddaughter of JFK, is dead at 35 after cancer diagnosis
- Pick Your Favored method of transportation
- Figure out How to Ascertain the Restitution Time frame for Your Sunlight based chargers
- Map shows more than 1,900 measles cases across U.S.
- 7 Powerful Techniques to Boost Efficiency with Your Cell Phone: A Thorough Aide
